The World Bank money will be in the form of grants or on 'highly concessional terms,' said David Malpass, president of the World BankFeb 1st 2021 · 1 min read
The World Bank money will be in the form of grants or on 'highly concessional terms,' said David Malpass, president of the World Bank
The World Bank has committed $12 billion to emerging countries, supporting vaccination programs that have failed to keep pace with those of developed nations.
The World Bank money will be in the form of grants or on “highly concessional terms," said David Malpass, president of the World Bank, in a statement following a Jan. 27 virtual meeting on the Africa Covid-19 vaccine financing and deployment strategy.
“We’re preparing emergency vaccine financing projects in 21 countries in Africa, including the Democratic Republic of Congo, Ethiopia, Niger, Mozambique, Tunisia, Eswatini and Cabo Verde to name a few," said Malpass. “The funds are available now," he said.
The cost of vaccinating 60% of Africa’s 1.3 billion people would be between $10 billion and $15 billion, according to the Africa Centres for Disease Control.
The continent has secured 36% of its vaccine needs, with 25% of the doses to come from the Covax initiative and 11% from a separate African Union program, Africa’s CDC said. But it’s far behind the rest of the world in terms of acquisition and inoculations, with richer nations having secured the scarce shots early.
“Since the outbreak of Covid-19 last March, the bank has committed $25 billion to African countries to support their health and economic recovery, and we expect to commit an additional $15 billion by June," Malpass said. “We urge leaders of African countries to move quickly to secure vaccinations for their populations, and to avail themselves of the financing available from us."
South Africa, the continent’s most industrialized nation, is one country that didn’t move quickly to secure vaccines. The first doses are due to arrive on Feb. 1 after widespread criticism of the government’s failure to sign bilateral agreements with drug makers in 2020.